1.A clinical evaluation of fluconazole as a single dose treatment for vaginal infections with candida.
Jun Hyun KIM ; Chong Hyun CHO ; Hyoung Moo PARK ; Do Hwan BAE
Korean Journal of Obstetrics and Gynecology 1992;35(9):1309-1316
No abstract available.
Candida*
;
Fluconazole*
2.Clinical efficacy of fluconazole in oropharyngeal and asophageal candidiasis.
Jong Dae JI ; Chul Won CHOI ; Goo LEE ; Jae Myung YOO ; Woo Joo KIM ; Jun Suk KIM ; Sung Shull PARK
Korean Journal of Infectious Diseases 1992;24(4):303-307
No abstract available.
Candidiasis*
;
Fluconazole*
3.A Case of Sporotrichosis Successfully Treated by Oral Fluconazole.
Moon Bum KIM ; Chang Keun OH ; Ho Sun JANG ; Kyung Sool KWON
Korean Journal of Medical Mycology 1999;4(2):148-152
No abstract abailble.
Fluconazole*
;
Sporotrichosis*
4.Prophylaxis of fungal infection with fluconazole in neutropenic patients.
Jung Baik KIM ; Wan Kyoo EO ; Shi Young KIM ; Hwi Joong YOON ; Kyung Sam CHO
Korean Journal of Infectious Diseases 1993;25(1):45-49
No abstract available.
Fluconazole*
;
Humans
5.Fluconazole effect in treatment of oral candidiasis.
Chan Soo MOON ; Sang Hoon LEE ; Wan Shik SHIN ; Moon Won KANG ; Jong Youl JIN ; Chong Won PARK ; Choon Choo KIM ; Dong Jip KIM ; Young LIM ; Im Goung YUN
Korean Journal of Infectious Diseases 1991;23(2):107-111
No abstract available.
Candidiasis, Oral*
;
Fluconazole*
6.A Case of Infantile Tinea Capitis Treated with Oral Fluconazole.
Soo Hyeon NOH ; Ga Hye NA ; Jin Kyung CHAE ; Kun PARK ; Eun Jung KIM
Korean Journal of Dermatology 2017;55(8):539-540
No abstract available.
Fluconazole*
;
Tinea Capitis*
;
Tinea*
7.Clinical evaluation of treatment with fluconazole in patients with vaginal candidiasis.
Jin Sub AHN ; Kyung Yeun CHA ; Jae I YANG ; Hee Sub RHEE ; Soo Kyeong HWANG ; Byung Chan OH ; Jong Duk KIM
Korean Journal of Obstetrics and Gynecology 1992;35(11):1613-1620
No abstract available.
Candidiasis*
;
Fluconazole*
;
Humans
8.Study on synthesis and measure biological effects of some fluconazole derivatives
Pharmaceutical Journal 2005;0(5):13-15
Fluconazol has been used as an effective antifungal drug for decades. However, increasing drug resistance make it becoming ineffective against many fungal strains. In search for new antifungal agents we have designed and synthesized eight derivatives of fluconazol, in which the hydroxy group of fluconazol was replaced by different functional groups, including halogens [Br (4a), Cl (4b), F (4c)}, azide (4d), cyanide (4e), carboxyl (4f), thiol (4g), and methanesulfonate (4h). Halogenated fluconazol derivatives (4a-4c) showed considerable antifungal activity against three fungal strains tested (C. albicans, A. niger, A. neoformans) with MIC values ranging from 139 to 552 mg/ml. Replacement of the -OH in fluconazol by bulkier groups like azide, cyanide, carboxyl, or methanesulfonate led to decrease or loss of antifungal activity. Exceptionally, however, a thiol derivative 4g (assigned UR/10289) exhibited very potent activity against all fungi tested, including two fluconazol-resistant strains (C. albicans, A. niger). This compound has been chosen as a candidate for further preclinical development by Parma Co. Ltd. (USA)
Fluconazole
;
Pharmaceutical Preparations
9.E-test for Antifungal Susceptibility Testing of Candida Species.
Min KIM ; Woo Hyun LIM ; Jong Hee SHIN ; Dong Wook RYANG
Korean Journal of Clinical Pathology 1999;19(1):78-85
BACKGROUND: Although standardized broth dilution methods for antifungal susceptibility testing are available, easier testing procedures are desirable. We evaluated the E-test (AB disk, Sweden) as a possible alternative instead of NCCLS (National Committee for Clinical Laboratory Standards) broth macrodilution method. METHODS: Fifty-two bloodstream isolates of Candida spp. (including 11 C. albicans, 13 C. tropicalis, 18 C. parapsilosis, 1 C. glabrata, 4 C. krusei, 2 C. pelliculosa, 2 C. lipolytica, and 1 C. guilliermondii) were tested. Amphotericin B and fluconazole MICs for each isolate were determined by both NCCLS broth macrodilution method and E-test. The results of E-test for Candida spp. were compared with those of NCCLS macrodilution method. For selecting plating media for E-test, we compared E-test results in two different media (RPMI and Casiton medium) using five ATCC Candida strains. RESULTS: As E-test media, we selected RPMI medium for amphotericin B and Casitone medium for fluconazole because of higher agreement with NCCLS method. The E-test and NCCLS method of 52 Candida spp. yielded a very narrow range of MICs (0.064-2.0 microgram/mL) for amphotericin B and a broad range of MICs (0.5-64 microgram/mL) for fluconazole. The agreements of E-test within one doubling dilutions of the macrodilution reference were 90.4% (24h and 48h) for amphotericin B, and 90.4% (24h) and 96.2% (48h) for fluconazole. CONCLUSION: The E-test is a valuable alternative to the NCCLS macrodilution method for amphotericin B and fluconazole susceptibility testing of Candida species.
Amphotericin B
;
Candida*
;
Fluconazole
10.Evaluation of Spectrophotometric Broth Microdilution Method to Determine the Fluconazole MIC of the Candida Species.
Ji Yon YI ; Jong Hee SHIN ; Kyung Won LEE ; Dong Eun YONG ; Myoung Jong CHAE ; Soon Pal SUH ; Dong Wook RYANG
The Korean Journal of Laboratory Medicine 2002;22(4):253-259
BACKGROUND: Although the broth microdilution method has been recently established for antifungal susceptibility testing of the Candida species, there is still an argue in the interpretation of the trailing endpoint. We evaluated the spectrophotometric broth microdilution method (SBM) to determine the fluconazole MICs from five different Candida species. METHODS: A total of 252 clinical isolates of five Candida species (144 C. albicans, 42 C. tropicalis, 32 C. glabrata, 28 C. parapsilosis, and 6 C. krusei) were tested for fluconazole susceptibility with the broth microdilution method. The MICs were spectrophotometrically determined at 80% (Spec-80%) and 50% (Spec-50%) decrease in absorbance as compared with growth control, respectively. The results were compared with the fluconazole MICs tested by the National Committee for the Clinical Laboratory Standards (NCCLS) macrodilution method. RESULTS: When MICs were obtained by Spec-80%, the agreements of SBM and the NCCLS macro dilution method within two doubling dilutions were 92.4% (220/238) at 24 h and 78.6% (198/252) at 48 h for all Candida species. Using the Spec-50%, those were increased to 97.9% (233/238) at 24 h and 98.8% (249/252) at 48 h (P<0.01). Especially, for C. albicans and C. tropicalis, the agreement of the Spec-50% was significantly higher than those of the Spec-80% at 48 h; 97.9% vs. 75.0%, for C. albicans (P<0.01), and 100% vs. 57.1%, for C. tropicalis (P<0.01). CONCLUSIONS: These data suggest that the SBM using Spec-50% can provide a more precise and objective mean for fluconazole susceptibility testing, especially for C. albicans and C. tropicalis.
Candida albicans
;
Candida*
;
Fluconazole*